| Primary | Number of Participants Receiving All Prescriptions and Injections of Denosumab From the Initial Prescribing Physician's Office | Number of participants who received all injection(s), including baseline injection, from the initial prescribing site irrespective of total number of injections received on study. | Full analysis set (all enrolled patients who provided informed consent and received at least one injection) | Posted | | Number | | participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Number of Participants Receiving an Individual Prescription and Injection of Denosumab From the Initial Prescribing Physician Office by Each Individual Injection | | Full analysis set; n = the number of participants who received the corresponding injection | Posted | | Number | | participants | | Baseline (day 1), and at Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively) | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Number of Participants Receiving All Prescriptions and Injections of Denosumab | Number of participants receiving all prescriptions and injections of denosumab whether or not the injections are given at the initial prescribing physician's office. | | Posted | | Number | | participants | | Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively) | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Number of Participants With a Referral by the Prescribing Physician to Other Health Care Providers for Continuation or Follow-up of Care | | Full analysis set participants who discontinued the study prematurely | Posted | | Number | | participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Types of Health Care Providers Administering an Individual Injection of Denosumab at the Baseline Injection | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the baseline injection. | | Posted | | Number | | participants | | Baseline (day 1) | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Types of Health Care Providers Administering Denosumab at the First Post-baseline Injection | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the first post-baseline injection. | Full analysis set participants who received a first post-baseline injection (i.e. at month 6) | Posted | | Number | | participants | | Month 6 | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Types of Health Care Providers Administering Denosumab at the Second Post-baseline Injection | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the second post-baseline injection. | Full analysis set participants who received a second post-baseline injection (i.e. at month 12) | Posted | | Number | | participants | | Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Types of Health Care Providers Administering Denosumab at the Third Post-baseline Injection | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the third post-baseline injection. | Full analysis set participants who received a third post-baseline injection (i.e. at month 18) | Posted | | Number | | participants | | Month 18 | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Types of Health Care Providers Administering Denosumab at the Fourth Post-baseline Injection | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the fourth post-baseline injection. | Full analysis set participants who received a fourth post-baseline injection (i.e. at month 24) | Posted | | Number | | participants | | Month 24 | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Number of Denosumab Post-baseline Injections Received by Each Participant | | | Posted | | Number | | participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Number of Participants Having Radiologic Bone Assessments | Number of participants having radiologic bone assessments pre-treatment with denosumab and during the study. | | Posted | | Number | | participants | | Pre-baseline (before first denosumab injection) and during the study (post-baseline) | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Primary | Number of Participants Having Osteoporosis Related Laboratory Examinations | Number of participants having osteoporosis related laboratory examinations pre-treatment with denosumab and during the study. Participants may not have been given denosumab injection when they attended each visit. | Full analysis set; n = participants with visits at each time point. | Posted | | Number | | participants | | Pre-baseline (before first denosumab injection) and post-baseline | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Secondary | Number of Participants With Adverse Drug Reactions (ADRs) to Denosumab | Adverse events (AEs) that were considered related to denosumab as evaluated by the investigator were classified as adverse drug reactions (ADRs). | | Posted | | Number | | participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |
| Secondary | Number of Participants With Serious ADRs to Denosumab | Serious adverse events that were considered related to denosumab were classified as serious adverse drug reactions (SADRs). A serious adverse event (SAE) is any AE that also: • is fatal • is life threatening (places the patient at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • is an "other significant medical hazard" that does not meet any of the above criteria. | | Posted | | Number | | participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | Czech Republic | Patients in the Czech Republic with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. | | OG001 | Slovakia | Patients in Slovakia with postmenopausal osteoporosis who received at least 1 injection of denosumab 60 mg administered subcutaneously every 6 months as part of their routine clinical care. |
| |